(Q50313366)

2 March 2018

title

Targeting of glycine site on NMDA receptor as a possible new strategy for autism treatment. (English)

1 reference

2 March 2018

0 references

Ahmad Ghanizadeh

1

1 reference

2 March 2018

publication date

6 January 2011

1 reference

2 March 2018

published in

Neurochemical Research

1 reference

2 March 2018

volume

36

1 reference

2 March 2018

issue

5

1 reference

2 March 2018

page(s)

922-923

1 reference

2 March 2018

https://scigraph.springernature.com/pub.10.1007/s11064-010-0381-2

exact match

0 references

cites work

Presynaptic glycine receptors influence plasma membrane potential and glutamate release

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Increased serum levels of glutamate in adult patients with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Plasma amino acid levels in children with autism and their families

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Modulation of N-methyl-D-aspartate receptor function by glycine transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Novel plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a putative causative mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Neurochemical correlates of autistic disorder: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Transplantation of GABAergic cell line as a novel hypothesized treatment for autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Leptin as a new approach for treatment for autism and epilepsy, a hypothesis with clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0381-2

Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone

21 January 2018

1 reference

12 December 2020

Neurochemistry in the pathophysiology of autism.

1 reference

12 December 2020

Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes

1 reference

12 December 2020

Memantine for disruptive behavior in autistic disorder.

1 reference

12 December 2020

c-Kit+ cells transplantation as a new treatment for autism, a novel hypothesis with important research and clinical implication.

1 reference

12 December 2020

Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument

1 reference

12 December 2020

Ghrelin as a promising therapeutic target for co-occurring autism and epilepsy.

1 reference

12 December 2020

The NMDA receptor complex: a long and winding road to therapeutics.

1 reference

12 December 2020

10.1007/S11064-010-0381-2

Identifiers

DOI

1 reference

2 March 2018

1 reference

2 March 2018